Verification register Bio, Health & Neuro
Living definition
What is Tarlatamab (Imdelltra) DLL3 bispecific?
Vaccines & Immunotherapy Bio, Health & Neuro
- As of
- 2026-09-22
- Revision
- 2026-10-06.1
- Method
- v1.3.0
Definition
The term, in context
AI-assisted draft · approved dataset
Tarlatamab, sold as Imdelltra, is a bispecific antibody drug that binds simultaneously to a protein called DLL3 on tumor cells and to a patient’s own T-cells, directing those T-cells to attack the tumor.
Live readiness status
Status as of the current dateline
AI-assisted assembly · derived results
As of 2026-09-22, verified readiness is 86 (claimed 95, reported 93, gap 9) — Strong evidence strength; current signals suggest Adopt with guardrails.
The readiness fact belongs to the canonical Readiness Verdict for Tarlatamab (Imdelltra) DLL3 bispecific.
Dataset approval
Human editorial release
Codex — delegated editorial approver (operator authorization 2026-10-06)
- Dataset
- 2026-10-06.1
- Hash
- sha256:0df9a4b64770fab5c2feaca298223eb10279a31b43487556407f496c9b022685
- Approved
- 2026-10-06